Medication info
Amozalton Q Tablets 5/100/10 mg (Amlodipine, Losartan, Rosuvastatin)

Amozalton Q Tablets 5/100/10 mg (Amlodipine, Losartan, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Camsylate›7.84mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tabletLosartan Potassium›100mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pale pink, oval, film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 201705684 · Approved 2017.07.14 · Insurance code 643507860

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk
Who takes it
Adults
Adult dose
This medication is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and rosuvastatin. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination is 1 tablet once daily in adults, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the expected degree of achievement of the treatment goal with the combination compared with the individual components. Usually, this medication is administered at 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ○ Patients with renal impairment: No dosage adjustment is necessary in patients with mild renal impairment (e.g., creatinine clearance 20∼50mL/min), but use of the amlodipine/losartan combination is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. ○ Patients with reduced intravascular effective circulating volume: Use of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular effective circulating volume (e.g., patients being treated with high-dose diuretics). (See section 1. Warnings under Precautions for Use.) ○ Patients with hepatic impairment: Use of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduction in the losartan dose (e.g., 25 mg once daily). ○ Older adults: In older adults aged 75 years or older, an initial losartan dose of 25 mg once daily is recommended; therefore, use of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose in adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. For patients taking the amlodipine/losartan combination and rosuvastatin concomitantly, they may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk

  • Essential hypertension
  • stage 2 hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
View approved original text

This drug is used for the treatment of hypertension by combining amlodipine and losartan while administering rosuvastatin to manage patients with hyperlipidemia. The amlodipine and losartan combination is used in essential hypertensive patients or stage 2 hypertensive patients who do not have sufficient blood pressure control to reach therapeutic goals. Rosuvastatin is used as an adjunct to dietary therapy for patients with hypercholesterolemia and mixed dyslipidemia and also helps with homozygous familial hypercholesterolemia. In addition, it is used to lower total cholesterol and LDL-cholesterol to slow the progression of atherosclerosis and reduce the risk of cardiovascular diseases, stroke, myocardial infarction, and the risk after vascular revascularization. This combination therapy improves both hypertension and hyperlipidemia conditions simultaneously.

How to take

Adult dose

This medication is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and rosuvastatin. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination is 1 tablet once daily in adults, taken with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not adequately controlled with monotherapy using the individual components, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the expected degree of achievement of the treatment goal with the combination compared with the individual components. Usually, this medication is administered at 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ○ Patients with renal impairment: No dosage adjustment is necessary in patients with mild renal impairment (e.g., creatinine clearance 20∼50mL/min), but use of the amlodipine/losartan combination is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. ○ Patients with reduced intravascular effective circulating volume: Use of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular effective circulating volume (e.g., patients being treated with high-dose diuretics). (See section 1. Warnings under Precautions for Use.) ○ Patients with hepatic impairment: Use of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduction in the losartan dose (e.g., 25 mg once daily). ○ Older adults: In older adults aged 75 years or older, an initial losartan dose of 25 mg once daily is recommended; therefore, use of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose in adults is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. For patients taking the amlodipine/losartan combination and rosuvastatin concomitantly, they may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can have serious effects on the fetus during pregnancy; therefore, if pregnancy is confirmed, it should be discontinued immediately. In particular, one of the components of this medication can affect fetal kidney function, leading to oligohydramnios, pulmonary hypoplasia, skeletal deformities, etc. Patients with severely low blood pressure or low blood volume may exhibit symptoms of hypotension, so their condition should be carefully checked before administration. Patients with allergies to any of the ingredients in this medication or with certain liver and kidney diseases should not take it. It is also necessary to exercise caution in patients with specific genetic metabolic disorders or a history of muscle-related diseases. The elderly or patients with weakened liver and kidney function should take this medication with more caution, and it is advisable to undergo regular blood tests and liver function tests. This medication can cause muscle aches, muscle weakness, and rarely severe muscle damage, so any abnormal symptoms in the muscles must be reported to healthcare providers immediately. When taken with other medications, interactions may occur, increasing the risk of side effects, so current medications must be communicated to healthcare providers. Especially when combined with potassium-sparing diuretics or potassium supplements, blood potassium levels may become dangerously elevated, hence attention is required. Women who are pregnant or planning pregnancy should avoid taking this medication and must use adequate contraception methods. If breastfeeding, it is essential to consult with healthcare providers before taking this medication, as the ingredients may be transmitted in breast milk. During the use of this medication, dizziness or symptoms of hypotension may occur; therefore, caution is needed when driving or operating machinery. If symptoms such as liver function abnormalities, severe muscle pain, or serious allergic reactions occur, discontinuation and consultation with healthcare providers are necessary.

Side effects

Upper respiratory infection, dizziness, dyspepsia, lower gastrointestinal bleeding, postural dizziness, syncope, rhabdomyolysis, pancreatic adenocarcinoma, dizziness, headache, drowsiness, cerebral infarction, asthenia, chest discomfort, chest pain, early satiety, peripheral edema, pitting edema, abdominal discomfort, nausea, gastroesophageal reflux disease, constipation, pruritus, urticaria, palpitations, flushing, orthostatic hypotension, facial flushing, dyspnea, cough, conjunctival injection, increased urinary frequency, angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, ALT elevation, chest pain, myalgia, CK elevation, asthenia, joint pain, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, vasculitis, tension increase, sensory loss, paresthesia, peripheral neuropathy, dysgeusia, tremor, extrapyramidal disorder, erectile dysfunction, gynecomastia, changes in bowel habits, dry mouth, gastritis, gingival hypertrophy, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, insomnia, mood changes, rhinitis, hair loss, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis, ringing in the ears, visual disturbances, increased urinary frequency, urinary disorders, nocturnal enuresis, hepatitis, jaundice, elevated liver enzymes, pruritus, rash, angioedema, erythema multiforme, myocardial infarction, arrhythmia, chest pain, hypotension, sinoatrial block, atrioventricular block, abdominal discomfort, precordial pain, diarrhea, loose stools, constipation, skin flushing, maculopapular rash, dizziness, heat sensation, impaired glucose tolerance, weakness, facial edema, fever, orthostatic effects, syncope, angina, second-degree atrioventricular block, cerebrovascular accident, hypotension, myocardial infarction, atrial fibrillation, palpitations, sinus bradycardia, tachycardia, ventricular tachycardia, ventricular fibrillation, anorexia, toothache, dry mouth, flatulence, gastritis, vomiting, anemia, gout, upper limb pain, hip joint pain, joint swelling, knee pain, muscle weakness, anxiety, anxiety disorder, ataxia, confusion, depression, nightmares, sensory impairment, decreased libido, memory impairment, migraine, neuro irritability, panic disorder, somnolence, tremor, bronchitis, pharyngeal discomfort, nasal bleeding, respiratory congestion, chest discomfort, hair loss, dermatitis, dry skin, petechiae, erythema, flushing, photosensitivity reactions, pruritus, rash, sweating, urticaria, blurred vision, burning sensation and pain in the eyes, conjunctivitis, dysgeusia, tinnitus, vision impairment, erectile dysfunction, nocturnal enuresis, increased urinary frequency, urethral infection, angioedema, vasculitis, anaphylactic-like syndrome, liver function abnormalities, hepatitis, intestinal vascular edema, weariness, anemia, thrombocytopenia, myalgia, weakness, creatine kinase elevation, increased serum and urinary myoglobin, rhabdomyolysis, dysgeusia, dry cough, erythema multiforme, hyperkalemia, hyponatremia, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, acute hepatitis, fulminant hepatitis, renal failure, ventricular extrasystole, atrial fibrillation, hypoglycemia, weakness, hunger, cold sweat, tremors, decreased concentration, seizures, altered consciousness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to store it at room temperature between 1 and 30 degrees Celsius. This will help maintain the drug's efficacy.

Appearance and packaging

Appearance

Pale pink, oval, film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.